These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25842186)

  • 1. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease.
    Doerfler PA; Nayak S; Herzog RW; Morel L; Byrne BJ
    Clin Immunol; 2015 Jun; 158(2):140-7. PubMed ID: 25842186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.
    Cresawn KO; Fraites TJ; Wasserfall C; Atkinson M; Lewis M; Porvasnik S; Liu C; Mah C; Byrne BJ
    Hum Gene Ther; 2005 Jan; 16(1):68-80. PubMed ID: 15703490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompe disease: current state of treatment modalities and animal models.
    Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE
    Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
    Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
    J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
    Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.
    Sun B; Kulis MD; Young SP; Hobeika AC; Li S; Bird A; Zhang H; Li Y; Clay TM; Burks W; Kishnani PS; Koeberl DD
    Mol Ther; 2010 Feb; 18(2):353-60. PubMed ID: 19690517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
    Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
    Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
    Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
    Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Variability in the clinical presentation of Pompe disease: development following enzyme replacement therapy].
    Ley-Martos M; Salado-Reyes MJ; Espinosa-Rosso R; Solera-García J; Jiménez-Jiménez L
    Rev Neurol; 2015 Nov; 61(9):416-20. PubMed ID: 26503317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse.
    Ohashi T; Iizuka S; Shimada Y; Eto Y; Ida H; Hachimura S; Kobayashi H
    Mol Genet Metab; 2011 May; 103(1):98-100. PubMed ID: 21320791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
    Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the T helper cell response to acid α-glucosidase in Pompe mice.
    Nayak S; Sivakumar R; Cao O; Daniell H; Byrne BJ; Herzog RW
    Mol Genet Metab; 2012 Jun; 106(2):189-95. PubMed ID: 22494547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.